What You Should Know:
– NEC X, the Silicon Valley venture studio backed by NEC’s portfolio of advanced technologies and global businesses, today announced a new investment in General Prognostics Inc.
– (GPx), a fast-growing MedTech startup revolutionizing chronic disease monitoring and management.
NEC X Invests in GPx to Advance Remote Blood Monitoring Solution for Heart Failure Patients
NEC X has invested in GPx as part of its strategic effort to foster healthcare innovation and address pressing challenges in chronic disease management. This investment aligns with NEC X’s vision of leveraging technology to improve healthcare access and reduce system burdens, particularly for patients with chronic conditions.
Coinciding with this investment, GPx has joined the Elev X! Boost program, a venture initiative designed to scale ambitious startups through a tailored blend of capital, strategic partnerships, and integrations within NEC X’s expansive tech ecosystem. Through Elev X! Boost, GPx will:
– Enhance the accuracy of its flagship product, **CardioID**—the world’s first implant- and needle-free remote blood monitoring solution for heart failure patients.
– Drive revenue growth, enter new markets, and secure further funding.
The CardioID system enables remote monitoring by extracting biomarkers from wearable devices, utilizing data such as heart rate, heart rate variability, step count, and voice. Through advanced machine learning, these biomarkers are analyzed to develop predictive models with accuracy exceeding that of traditional implant-based systems.
GPx’s leadership team brings robust expertise in healthcare and medical devices. The team, composed of graduates from MIT and Harvard, includes co-founders **Sean Matsuoka** and Javier Echenique, whose backgrounds span leadership roles at firms like Caresyntax, M3, McKinsey & Company, Sony Corporation, Jana Care, Medtronic, and Volcano. Founding advisor Sidhant Jena also contributes significant experience, having co-founded and led Jana Care as CEO and held R&D leadership roles at Medtronic.
This partnership with NEC X will accelerate GPx’s growth trajectory as it prepares to scale operations and bring CardioID to market, setting new standards for non-invasive, real-time cardiac monitoring.
“GPx’s innovative approach to heart monitoring and chronic disease management is a perfect fit for the NEC Group’s vision of leveraging advanced technology to improve quality of life,” said Shintaro Matsumoto, President and CEO of NEC X. “By joining forces with GPx, we aim to enhance their predictive algorithms and capabilities. Together, we can transform the healthcare industry.”